Biomarkers and Therapy Options for Castration Resistance Prostate Cancer: Where Are We Now?

Call for Papers

Prostate adenocarcinoma still ranks as the second most commonly diagnosed cancer. Although advanced disease is initially sensitive to androgen deprivation therapy (ADT), most deaths occur following progression toward castration-resistant prostate cancer (CRPC), which is currently incurable, metastatic, and resistant to ADT. CRPC is a fatal manifestation of prostate cancer and significant efforts are underway to better understand this phase of the disease and develop treatments. At present we understand that there is a significant degree of heterogeneity amongst CRPC patients with different profiles of progression. Hence, CRPC requires specialized care which is a therapeutic challenge.

Another major issue that needs to be urgently addressed is the discovery and development of biomarkers for early cancer detection, to improve patient survival. Prostate-specific antigen (PSA) is currently commonly used as a screening biomarker for prostate cancer, but it has limitations in both sensitivity and specificity. Finally, prostate cancer cells have high tropism for bone and stimulate osteoblast proliferation and differentiation. It was suggested that prostate cancer cells should induce new bone formation by activating bone-development programs in osteoblasts.

In this special issue for the BioMed Research International (http://www.hindawi.com/journals/bmri/), we invite investigators to contribute original research articles, as well as reviews, which will inform, instruct, and provide an overview of the latest findings related to all the aspects to improve CRPC diagnosis and therapy. Potential topics include, but are not limited to:

• Novel biomarkers for prognosis, monitoring of therapy, and treatment for CRPC
• Use, limitations, and specificity of known biomarkers that can be detected in both serum and urine for CRPC
• Biology underlying CRPC
• Clinical studies and clinical trials for CRPC
• Novel anticancer drugs or combinations for CRPC
• Factors that influence CRPC progression including obesity, age, and family history
• Polymorphisms that influence response to CRPC therapy
• Biology of prostate cancer bone metastases
• Bone metastases biomarkers
• Bone metastases therapy

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/oncology/crpc/ according to the following timetable:

Lead Guest Editor

• Adriana De Siervi, University of Buenos Aires (UBA), Argentina

Guest Editors

• Nora Navone, The University of Texas MD Anderson Cancer Center, USA
• Daniel Compagno, University of Buenos Aires (UBA), Argentina
• Elba Vazquez, University of Buenos Aires, Argentina